Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):879-881. doi: 10.4093/dmj.2023.0328. Epub 2023 Nov 24.NO ABSTRACTPMID:38043783 | PMC:PMC10695716 | DOI:10.4093/dmj.2023.0328 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Da Young Lee Source Type: research
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):882-883. doi: 10.4093/dmj.2023.0355. Epub 2023 Nov 24.NO ABSTRACTPMID:38043784 | PMC:PMC10695721 | DOI:10.4093/dmj.2023.0355 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Nikolai N Scherbak Robert Kruse Thomas Nystr öm Johan Jendle Source Type: research
Ensuring Heathy Lives with the Korea Disease Control and Prevention Agency: Partnership with the Korean Diabetes Association
Diabetes Metab J. 2023 Nov;47(6):767-768. doi: 10.4093/dmj.2023.0406. Epub 2023 Nov 24.NO ABSTRACTPMID:38043780 | PMC:PMC10695713 | DOI:10.4093/dmj.2023.0406 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Youngmee Jee Source Type: research
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Diabetes Metab J. 2023 Nov;47(6):769-770. doi: 10.4093/dmj.2023.0351. Epub 2023 Nov 24.NO ABSTRACTPMID:38043781 | PMC:PMC10695718 | DOI:10.4093/dmj.2023.0351 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Sang Youl Rhee Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):879-881. doi: 10.4093/dmj.2023.0328. Epub 2023 Nov 24.NO ABSTRACTPMID:38043783 | PMC:PMC10695716 | DOI:10.4093/dmj.2023.0328 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Da Young Lee Source Type: research
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):882-883. doi: 10.4093/dmj.2023.0355. Epub 2023 Nov 24.NO ABSTRACTPMID:38043784 | PMC:PMC10695721 | DOI:10.4093/dmj.2023.0355 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Nikolai N Scherbak Robert Kruse Thomas Nystr öm Johan Jendle Source Type: research
Ensuring Heathy Lives with the Korea Disease Control and Prevention Agency: Partnership with the Korean Diabetes Association
Diabetes Metab J. 2023 Nov;47(6):767-768. doi: 10.4093/dmj.2023.0406. Epub 2023 Nov 24.NO ABSTRACTPMID:38043780 | PMC:PMC10695713 | DOI:10.4093/dmj.2023.0406 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Youngmee Jee Source Type: research
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Diabetes Metab J. 2023 Nov;47(6):769-770. doi: 10.4093/dmj.2023.0351. Epub 2023 Nov 24.NO ABSTRACTPMID:38043781 | PMC:PMC10695718 | DOI:10.4093/dmj.2023.0351 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Sang Youl Rhee Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):879-881. doi: 10.4093/dmj.2023.0328. Epub 2023 Nov 24.NO ABSTRACTPMID:38043783 | PMC:PMC10695716 | DOI:10.4093/dmj.2023.0328 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Da Young Lee Source Type: research
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):882-883. doi: 10.4093/dmj.2023.0355. Epub 2023 Nov 24.NO ABSTRACTPMID:38043784 | PMC:PMC10695721 | DOI:10.4093/dmj.2023.0355 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Nikolai N Scherbak Robert Kruse Thomas Nystr öm Johan Jendle Source Type: research
Ensuring Heathy Lives with the Korea Disease Control and Prevention Agency: Partnership with the Korean Diabetes Association
Diabetes Metab J. 2023 Nov;47(6):767-768. doi: 10.4093/dmj.2023.0406. Epub 2023 Nov 24.NO ABSTRACTPMID:38043780 | PMC:PMC10695713 | DOI:10.4093/dmj.2023.0406 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Youngmee Jee Source Type: research
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Diabetes Metab J. 2023 Nov;47(6):769-770. doi: 10.4093/dmj.2023.0351. Epub 2023 Nov 24.NO ABSTRACTPMID:38043781 | PMC:PMC10695718 | DOI:10.4093/dmj.2023.0351 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Sang Youl Rhee Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
